Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00822120
Other study ID # CDR0000630501
Secondary ID S0816U10CA032102
Status Completed
Phase Phase 2
First received
Last updated
Start date July 2009
Est. completion date June 30, 2022

Study information

Verified date August 2022
Source Southwest Oncology Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. G-CSF may help lessen the side effects in patients receiving chemotherapy. Imaging procedures, such as fludeoxyglucose F 18-PET/CT imaging, may help doctors predict how patients will respond to treatment. PURPOSE: This phase II trial is studying fludeoxyglucose F 18-PET/CT imaging to see how well it works in assessing response to combination chemotherapy and allow doctors to plan better additional further treatment in treating patients with stage III or stage IV Hodgkin lymphoma.


Description:

OBJECTIVES: Primary - To estimate the 2-year progression-free survival (PFS) of HIV-negative patients with stage III-IV Hodgkin lymphoma treated with response-adapted therapy based on fludeoxyglucose F 18 (FDG)-PET imaging after 2 courses of doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine (ABVD). - To estimate the 2-year PFS of patients who are PET-positive after treatment with 2 courses of ABVD and an escalated dose regimen comprising cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, bleomycin, procarbazine hydrochloride, and prednisone (BEACOPP). Secondary - To estimate the 2-year overall survival (OS) of patients treated with these regimens. - To estimate the response rate (i.e., complete and partial responses) in patients treated with these regimens. - To evaluate the toxicity of these response-adapted regimens. - To document the feasibility of centralized, real-time review of FDG-PET imaging for U.S. cooperative group studies. - To prospectively evaluate the overall response rate, complete response rate, PFS, and OS of HIV-positive patients treated with these response-adapted regimens. OUTLINE: This is a multicenter study. All patients undergo baseline whole-body fludeoxyglucose F 18 (FDG)-PET/CT imaging before beginning chemotherapy. Patients then receive doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and dacarbazine IV (ABVD) on days 1 and 15. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Between days 22 and 25 of course 2, patients undergo a second FDG-PET/CT scan to assess response. Subsequent therapy is based on FDG-PET/CT scan results. Patients are stratified according to FDG-PET positivity (yes vs no). Patients who are FDG-PET-negative continue treatment with ABVD for up to 4 additional courses in the absence of disease progression or unacceptable toxicity. Patients who are FDG-PET-positive are then further stratified according to HIV positivity (yes or no) and receive 1 of the following treatment regimens: - Escalated-dose BEACOPP chemotherapy: HIV-negative patients receive escalated-dose BEACOPP chemotherapy comprising doxorubicin hydrochloride IV and cyclophosphamide IV on day 1, etoposide IV on days 1-3, oral procarbazine hydrochloride on days 1-7, oral prednisone on days 1-14, and bleomycin IV and vincristine IV on day 8. Patients receive filgrastim (G-CSF) subcutaneously on days 8-14. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. - Standard-dose BEACOPP chemotherapy: HIV-positive patients receive standard dose BEACOPP chemotherapy comprising doxorubicin hydrochloride IV and cyclophosphamide IV on day 1, etoposide IV on days 1-3, oral procarbazine hydrochloride on days 1-7, oral prednisone on days 1-14, and bleomycin IV and vincristine IV on day 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Six to eight weeks after completion of chemotherapy, patients undergo a post-treatment FDG-PET/CT scan. Some patients may undergo bone marrow biopsy at 1 month after the last course of chemotherapy. After completion of study treatment, patients are followed up periodically for 7 years.


Recruitment information / eligibility

Status Completed
Enrollment 371
Est. completion date June 30, 2022
Est. primary completion date April 30, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility DISEASE CHARACTERISTICS: - Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted) - Previously untreated stage III or IV disease - No nodular lymphocyte predominant disease - Bidimensionally measurable disease - Adequate biopsy samples from original diagnostic specimen must be available for pathologic review - Tissue obtained from core biopsies allowed - No tissue obtained from needle aspirations or cytologies - Must have known HIV status - No multi-drug resistant HIV infection, CD4 counts < 150/µL, or other concurrent AIDS-defining conditions in HIV-positive patients - HIV-positive patients with CD4 counts = 150/µL at the time of enrollment OR documented CD4 count > 250/µL at any time within 8 months prior to HL diagnosis allowed - Must have undergone unilateral or bilateral bone marrow biopsy within the past 42 days - Must have a diagnostic quality CT scan of the chest/abdomen and pelvis AND baseline FDG-PET scan within the past 28 days - Combined PET/CT scans required - No older "stand-alone" FDG-PET scans - No low-resolution "localization" CT scans as part of a combined PET/CT scans PATIENT CHARACTERISTICS: - Zubrod performance status 0-2 - Serum erythrocyte sedimentation rate, lactate dehydrogenase (LDH), hemoglobin, albumin, white blood cell count (WBC), and lymphocytes measured within the past 28 days - Serum estradiol (women only), testosterone (men only), follicle stimulating hormone (FSH) and luteinizing hormone (LH) (both men and women) levels must be drawn within 60 days prior to registration - Not pregnant or nursing - Fertile patients must use effective contraception during and for = 6 months after completion of study therapy - No significant cardiac abnormalities as assessed by multiple gated acquisition scan (MUGA) or ECHO AND cardiac ejection fraction = 45% in patients with a history of hypertension or cardiac symptoms - Hepatitis B-negative (i.e., hepatitis B surface antigen-negative or anti-hepatitis B core antigen-negative) - Patients immune to or immunized against hepatitis B (i.e., anti-hepatitis B surface antibody-positive) are eligible - Hepatitis C-negative (i.e., anti-hepatitis C antibody-negative) - No significant lung disease with abnormal lung function tests (i.e., diffusing capacity of lung for carbon monoxide (DLCO) > 25% below predicted after correction for hemoglobin) unless attributable to lymphoma - No requirement for continuous supplemental oxygen therapy - No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No prior chemotherapy, radiotherapy, or antibody therapy for lymphoma - No prior solid organ transplantation

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
bleomycin sulfate

filgrastim

Drug:
ABVD regimen

BEACOPP regimen

cyclophosphamide

dacarbazine

doxorubicin hydrochloride

etoposide

prednisone

procarbazine hydrochloride

vinblastine sulfate

vincristine sulfate


Locations

Country Name City State
United States Kapiolani Medical Center at Pali Momi 'Aiea Hawaii
United States Hickman Cancer Center at Bixby Medical Center Adrian Michigan
United States Summa Center for Cancer Care at Akron City Hospital Akron Ohio
United States University of New Mexico Cancer Center Albuquerque New Mexico
United States Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest Allentown Pennsylvania
United States Island Hospital Cancer Care Center at Island Hospital Anacortes Washington
United States Kaiser Permanente Medical Center - Anaheim/Orange County Anaheim California
United States AnMed Cancer Center Anderson South Carolina
United States CCOP - Michigan Cancer Research Consortium Ann Arbor Michigan
United States Saint Joseph Mercy Cancer Center Ann Arbor Michigan
United States University of Michigan Comprehensive Cancer Center Ann Arbor Michigan
United States Kaiser Permanente - Deer Valley Antioch California
United States Northeast Georgia Cancer Care, LLC - Medical Oncology Athens Georgia
United States Winship Cancer Institute of Emory University Atlanta Georgia
United States MBCCOP - Medical College of Georgia Cancer Center Augusta Georgia
United States Aurora Presbyterian Hospital Aurora Colorado
United States Kaiser Permanente Medical Center - Baldwin Park Baldwin Park California
United States Alvin and Lois Lapidus Cancer Institute at Sinai Hospital Baltimore Maryland
United States Greater Baltimore Medical Center Cancer Center Baltimore Maryland
United States Greenebaum Cancer Center at University of Maryland Medical Center Baltimore Maryland
United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland
United States Barberton Citizens Hospital Barberton Ohio
United States Mary Bird Perkins Cancer Center - Baton Rouge Baton Rouge Louisiana
United States Ochsner Health Center - Bluebonnet Baton Rouge Louisiana
United States Battle Creek Health System Cancer Care Center Battle Creek Michigan
United States St. Francis Hospital and Health Centers - Beech Grove Campus Beech Grove Indiana
United States Overlake Cancer Center at Overlake Hospital Medical Center Bellevue Washington
United States Kaiser Permanente Medical Center - Bellflower Bellflower California
United States St. Joseph Cancer Center Bellingham Washington
United States Mountainview Medical Berlin Vermont
United States National Naval Medical Center Bethesda Maryland
United States Mecosta County Medical Center Big Rapids Michigan
United States Billings Clinic - Downtown Billings Montana
United States CCOP - Montana Cancer Consortium Billings Montana
United States Hematology-Oncology Centers of the Northern Rockies - Billings Billings Montana
United States St. Vincent Healthcare Cancer Care Services Billings Montana
United States Medcenter One Hospital Cancer Care Center Bismarck North Dakota
United States Mid Dakota Clinic, PC Bismarck North Dakota
United States St. Alexius Medical Center Cancer Center Bismarck North Dakota
United States Illinois CancerCare - Bloomington Bloomington Illinois
United States St. Joseph Medical Center Bloomington Illinois
United States Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center Boise Idaho
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Boston University Cancer Research Center Boston Massachusetts
United States Dana-Farber/Brigham and Women's Cancer Center Boston Massachusetts
United States Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Boston Massachusetts
United States Boulder Community Hospital Boulder Colorado
United States Wood County Oncology Center Bowling Green Ohio
United States Bozeman Deaconess Cancer Center Bozeman Montana
United States Olympic Hematology and Oncology Bremerton Washington
United States Albert Einstein Cancer Center at Albert Einstein College of Medicine Bronx New York
United States Highline Medical Center Cancer Center Burien Washington
United States Fletcher Allen Health Care - University Health Center Campus Burlington Vermont
United States Fairview Ridges Hospital Burnsville Minnesota
United States St. James Healthcare Cancer Care Butte Montana
United States Graham Hospital Canton Illinois
United States Illinois CancerCare - Canton Canton Illinois
United States Illinois CancerCare - Carthage Carthage Illinois
United States Memorial Hospital Carthage Illinois
United States Rocky Mountain Oncology Casper Wyoming
United States Providence Centralia Hospital Centralia Washington
United States Cancer Center of Kansas, PA - Chanute Chanute Kansas
United States Hollings Cancer Center at Medical University of South Carolina Charleston South Carolina
United States John H. Stroger, Jr. Hospital of Cook County Chicago Illinois
United States University of Chicago Cancer Research Center Chicago Illinois
United States Clackamas Radiation Oncology Center Clackamas Oregon
United States Case Comprehensive Cancer Center Cleveland Ohio
United States Cleveland Clinic Taussig Cancer Center Cleveland Ohio
United States Penrose Cancer Center at Penrose Hospital Colorado Springs Colorado
United States Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center Columbus Ohio
United States Mercy and Unity Cancer Center at Mercy Hospital Coon Rapids Minnesota
United States Ochsner Health Center - Covington Covington Louisiana
United States Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Dallas Texas
United States Geisinger Cancer Institute at Geisinger Health Danville Pennsylvania
United States CCOP - Dayton Dayton Ohio
United States David L. Rike Cancer Center at Miami Valley Hospital Dayton Ohio
United States Good Samaritan Hospital Dayton Ohio
United States Grandview Hospital Dayton Ohio
United States Samaritan North Cancer Care Center Dayton Ohio
United States Oakwood Cancer Center at Oakwood Hospital and Medical Center Dearborn Michigan
United States Decatur Memorial Hospital Cancer Care Institute Decatur Illinois
United States CCOP - Colorado Cancer Research Program Denver Colorado
United States Kaiser Permanente - Denver Denver Colorado
United States Porter Adventist Hospital Denver Colorado
United States Presbyterian - St. Luke's Medical Center Denver Colorado
United States Rose Medical Center Denver Colorado
United States St. Anthony Central Hospital Denver Colorado
United States St. Joseph Hospital Denver Colorado
United States Barbara Ann Karmanos Cancer Institute Detroit Michigan
United States Josephine Ford Cancer Center at Henry Ford Hospital Detroit Michigan
United States Cancer Center of Kansas, PA - Dodge City Dodge City Kansas
United States City of Hope Comprehensive Cancer Center Duarte California
United States CCOP - Duluth Duluth Minnesota
United States Duluth Clinic Cancer Center - Duluth Duluth Minnesota
United States Miller - Dwan Medical Center Duluth Minnesota
United States Center for Cancer Treatment & Prevention at Sacred Heart Hospital Eau Claire Wisconsin
United States Marshfield Clinic Cancer Care at Regional Cancer Center Eau Claire Wisconsin
United States Fairview Southdale Hospital Edina Minnesota
United States Cancer Center of Kansas, PA - El Dorado El Dorado Kansas
United States Sherman Hospital Elgin Illinois
United States Union Hospital of Cecil County Elkton Maryland
United States Community Cancer Center Elyria Ohio
United States Hematology Oncology Center Elyria Ohio
United States Swedish Medical Center Englewood Colorado
United States Green Bay Oncology, Limited - Escanaba Escanaba Michigan
United States Eureka Community Hospital Eureka Illinois
United States Illinois CancerCare - Eureka Eureka Illinois
United States Providence Regional Cancer Partnership Everett Washington
United States St. Francis Hospital Federal Way Washington
United States Blanchard Valley Medical Associates Findlay Ohio
United States Genesys Hurley Cancer Institute Flint Michigan
United States Hurley Medical Center Flint Michigan
United States Kaiser Permanente Medical Center - Fontana Fontana California
United States Front Range Cancer Specialists Fort Collins Colorado
United States Poudre Valley Hospital Fort Collins Colorado
United States Cancer Center of Kansas - Fort Scott Fort Scott Kansas
United States Fort Wayne Medical Oncology and Hematology Fort Wayne Indiana
United States Middletown Regional Hospital Franklin Ohio
United States Fredericksburg Oncology, Incorporated Fredericksburg Virginia
United States Kaiser Permanente - Fremont Fremont California
United States Kaiser Permanente Fresno Medical Center Fresno California
United States Mercy and Unity Cancer Center at Unity Hospital Fridley Minnesota
United States Galesburg Clinic, PC Galesburg Illinois
United States Illinois CancerCare - Galesburg Galesburg Illinois
United States Delnor Hospital - Geneva Geneva Illinois
United States Addison Gilbert Hospital Gloucester Massachusetts
United States Wayne Memorial Hospital, Incorporated Goldsboro North Carolina
United States Genesys Regional Medical Center Grand Blanc Michigan
United States St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center Grand Junction Colorado
United States Butterworth Hospital at Spectrum Health Grand Rapids Michigan
United States CCOP - Grand Rapids Grand Rapids Michigan
United States Lacks Cancer Center at Saint Mary's Health Care Grand Rapids Michigan
United States Great Falls Clinic - Main Facility Great Falls Montana
United States Sletten Cancer Institute at Benefis Healthcare Great Falls Montana
United States North Colorado Medical Center Greeley Colorado
United States Green Bay Oncology, Limited at St. Mary's Hospital Green Bay Wisconsin
United States Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center Green Bay Wisconsin
United States St. Mary's Hospital Medical Center - Green Bay Green Bay Wisconsin
United States St. Vincent Hospital Regional Cancer Center Green Bay Wisconsin
United States Bon Secours St. Francis Health System Greenville South Carolina
United States Wayne Hospital Greenville Ohio
United States Legacy Mount Hood Medical Center Gresham Oregon
United States Van Elslander Cancer Center at St. John Hospital and Medical Center Grosse Pointe Woods Michigan
United States Cancer Institute of New Jersey at Hamilton Hamilton New Jersey
United States Kaiser Permanente Medical Center - Harbor City Harbor City California
United States Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center Hartford Connecticut
United States Illinois CancerCare - Havana Havana Illinois
United States Kaiser Permanente Medical Center - Hayward Hayward California
United States Geisinger Hazleton Cancer Center Hazleton Pennsylvania
United States St. Peter's Hospital Helena Montana
United States Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center Hershey Pennsylvania
United States Cancer Research Center of Hawaii Honolulu Hawaii
United States Hawaii Medical Center - East Honolulu Hawaii
United States Kaiser Permanente - Moanalua Medical Center and Clinic Honolulu Hawaii
United States Kapiolani Medical Center for Women and Children Honolulu Hawaii
United States OnCare Hawaii, Incorporated - Kuakini Honolulu Hawaii
United States OnCare Hawaii, Incorporated - Lusitana Honolulu Hawaii
United States Queen's Cancer Institute at Queen's Medical Center Honolulu Hawaii
United States Straub Clinic and Hospital, Incorporated Honolulu Hawaii
United States Tripler Army Medical Center Honolulu Hawaii
United States M. D. Anderson Cancer Center at University of Texas Houston Texas
United States Hutchinson Area Health Care Hutchinson Minnesota
United States Cancer Center of Kansas-Independence Independence Kansas
United States Dickinson County Healthcare System Iron Mountain Michigan
United States Kaiser Permanente - Irvine Irvine California
United States Swedish Medical Center - Issaquah Campus Issaquah Washington
United States Foote Memorial Hospital Jackson Michigan
United States West Tennessee Cancer Center at Jackson-Madison County General Hospital Jackson Tennessee
United States UW Cancer Center Johnson Creek Johnson Creek Wisconsin
United States Castle Medical Center Kailua Hawaii
United States Borgess Medical Center Kalamazoo Michigan
United States Bronson Methodist Hospital Kalamazoo Michigan
United States West Michigan Cancer Center Kalamazoo Michigan
United States Glacier Oncology, PLLC Kalispell Montana
United States Kalispell Medical Oncology at KRMC Kalispell Montana
United States Kalispell Regional Medical Center Kalispell Montana
United States Heartland Hematology Oncology Associates, Incorporated Kansas City Missouri
United States North Kansas City Hospital Kansas City Missouri
United States Providence Medical Center Kansas City Kansas
United States Research Medical Center Kansas City Missouri
United States Saint Luke's Cancer Institute at Saint Luke's Hospital Kansas City Missouri
United States Columbia Basin Hematology Kennewick Washington
United States Charles F. Kettering Memorial Hospital Kettering Ohio
United States Illinois CancerCare - Kewanee Clinic Kewanee Illinois
United States Cancer Center of Kansas, PA - Kingman Kingman Kansas
United States Gundersen Lutheran Center for Cancer and Blood La Crosse Wisconsin
United States Rebecca and John Moores UCSD Cancer Center La Jolla California
United States Kaiser Permanente - Lafayette Lafayette Colorado
United States Sparrow Regional Cancer Center Lansing Michigan
United States CCOP - Nevada Cancer Research Foundation Las Vegas Nevada
United States University Medical Center of Southern Nevada Las Vegas Nevada
United States Lawrence Memorial Hospital Lawrence Kansas
United States Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center Lebanon New Hampshire
United States Saint Luke's East - Lee's Summit Lee's Summit Missouri
United States Tunnell Cancer Center at Beebe Medical Center Lewes Delaware
United States St. Joseph Regional Medical Center Lewiston Idaho
United States Lewistown Hospital Lewistown Pennsylvania
United States Lucille P. Markey Cancer Center at University of Kentucky Lexington Kentucky
United States Cancer Center of Kansas, PA - Liberal Liberal Kansas
United States Parvin Radiation Oncology Liberty Missouri
United States Kauai Medical Clinic Lihue Hawaii
United States Lima Memorial Hospital Lima Ohio
United States Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock Arkansas
United States Littleton Adventist Hospital Littleton Colorado
United States St. Mary Mercy Hospital Livonia Michigan
United States Sky Ridge Medical Center Lone Tree Colorado
United States Hope Cancer Care Center at Longmont United Hospital Longmont Colorado
United States Kaiser Foundation Hospital - West Los Angeles Los Angeles California
United States Kaiser Permanente Medical Center - Los Angeles Los Angeles California
United States Louisville Oncology at Norton Cancer Institute - Louisville Louisville Kentucky
United States McKee Medical Center Loveland Colorado
United States Illinois CancerCare - Macomb Macomb Illinois
United States McDonough District Hospital Macomb Illinois
United States University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison Wisconsin
United States Manchester Memorial Hospital Manchester Connecticut
United States Holy Family Memorial Medical Center Cancer Care Center Manitowoc Wisconsin
United States HealthEast Cancer Care at St. John's Hospital Maplewood Minnesota
United States Minnesota Oncology - Maplewood Maplewood Minnesota
United States Bay Area Cancer Care Center at Bay Area Medical Center Marinette Wisconsin
United States Marshfield Clinic - Marshfield Center Marshfield Wisconsin
United States Saint Joseph's Hospital Marshfield Wisconsin
United States Ravenel Oncology Center at Memorial Hospital of Martinsville and Henry County Martinsville Virginia
United States Northwest Ohio Oncology Center Maumee Ohio
United States Cardinal Bernardin Cancer Center at Loyola University Medical Center Maywood Illinois
United States Cancer Center of Kansas, PA - McPherson McPherson Kansas
United States Idaho Urologic Institute, PA Meridian Idaho
United States Tucker Center for Cancer Care at Orange Regional Medical Center Middletown New York
United States Providence Milwaukie Hospital Milwaukie Oregon
United States Hennepin County Medical Center - Minneapolis Minneapolis Minnesota
United States Virginia Piper Cancer Institute at Abbott - Northwestern Hospital Minneapolis Minnesota
United States Marshfield Clinic - Lakeland Center Minocqua Wisconsin
United States Montana Cancer Center at St. Patrick Hospital and Health Sciences Center Missoula Montana
United States Montana Cancer Specialists at Montana Cancer Center Missoula Montana
United States Illinois CancerCare - Monmouth Monmouth Illinois
United States OSF Holy Family Medical Center Monmouth Illinois
United States Community Cancer Center of Monroe Monroe Michigan
United States Mercy Memorial Hospital - Monroe Monroe Michigan
United States Mary Babb Randolph Cancer Center at West Virginia University Hospitals Morgantown West Virginia
United States Skagit Valley Hospital Cancer Care Center Mount Vernon Washington
United States D.N. Greenwald Center Mukwonago Wisconsin
United States Mercy General Health Partners Muskegon Michigan
United States Vanderbilt-Ingram Cancer Center Nashville Tennessee
United States Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick New Jersey
United States Yale Cancer Center New Haven Connecticut
United States CCOP - Ochsner New Orleans Louisiana
United States MBCCOP - LSU Health Sciences Center New Orleans Louisiana
United States Medical Center of Louisiana - New Orleans New Orleans Louisiana
United States Ochsner Cancer Institute at Ochsner Clinic Foundation New Orleans Louisiana
United States New Ulm Medical Center New Ulm Minnesota
United States Beth Israel Medical Center - Petrie Division New York New York
United States Memorial Sloan-Kettering Cancer Center New York New York
United States St. Luke's - Roosevelt Hospital Center - St.Luke's Division New York New York
United States CCOP - Christiana Care Health Services Newark Delaware
United States Providence Newberg Medical Center Newberg Oregon
United States Cancer Center of Kansas, PA - Newton Newton Kansas
United States BroMenn Regional Medical Center Normal Illinois
United States Community Cancer Center Normal Illinois
United States Illinois CancerCare - Community Cancer Center Normal Illinois
United States Kaiser Permanente Medical Center - Oakland Oakland California
United States Regional Cancer Center at Oconomowoc Memorial Hospital Oconomowoc Wisconsin
United States Green Bay Oncology, Limited - Oconto Falls Oconto Falls Wisconsin
United States Providence St. Peter Hospital Regional Cancer Center Olympia Washington
United States UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha Nebraska
United States St. Charles Mercy Hospital Oregon Ohio
United States Toledo Clinic - Oregon Oregon Ohio
United States Willamette Falls Hospital Oregon City Oregon
United States M.D. Anderson Cancer Center at Orlando Orlando Florida
United States Community Hospital of Ottawa Ottawa Illinois
United States Oncology Hematology Associates of Central Illinois, PC - Ottawa Ottawa Illinois
United States Menorah Medical Center Overland Park Kansas
United States Saint Luke's Hospital - South Overland Park Kansas
United States Kaiser Permanente Medical Group Panorama City California
United States Parker Adventist Hospital Parker Colorado
United States Cancer Center of Kansas, PA - Parsons Parsons Kansas
United States Cancer Treatment Center at Pekin Hospital Pekin Illinois
United States Illinois CancerCare - Pekin Pekin Illinois
United States CCOP - Illinois Oncology Research Association Peoria Illinois
United States Methodist Medical Center of Illinois Peoria Illinois
United States Oncology Hematology Associates of Central Illinois, PC - Peoria Peoria Illinois
United States OSF St. Francis Medical Center Peoria Illinois
United States Proctor Hospital Peoria Illinois
United States Illinois CancerCare - Peru Peru Illinois
United States Illinois Valley Community Hospital Peru Illinois
United States Joan Karnell Cancer Center at Pennsylvania Hospital Philadelphia Pennsylvania
United States FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center Pinehurst North Carolina
United States St. Joseph Mercy Oakland Pontiac Michigan
United States Mercy Regional Cancer Center at Mercy Hospital Port Huron Michigan
United States CCOP - Columbia River Oncology Program Portland Oregon
United States Legacy Emanuel Hospital and Health Center and Children's Hospital Portland Oregon
United States Legacy Good Samaritan Hospital & Comprehensive Cancer Center Portland Oregon
United States Providence Cancer Center at Providence Portland Medical Center Portland Oregon
United States Providence St. Vincent Medical Center Portland Oregon
United States Harrison Poulsbo Hematology and Onocology Poulsbo Washington
United States CCOP - Kansas City Prairie Village Kansas
United States Cancer Center of Kansas, PA - Pratt Pratt Kansas
United States Illinois CancerCare - Princeton Princeton Illinois
United States Perry Memorial Hospital Princeton Illinois
United States St. Mary - Corwin Regional Medical Center Pueblo Colorado
United States Good Samaritan Cancer Center Puyallup Washington
United States Kaiser Permanente Medical Center - Redwood City Redwood City California
United States Spectrum Health Reed City Hospital Reed City Michigan
United States Ministry Medical Group at Saint Mary's Hospital Rhinelander Wisconsin
United States Marshfield Clinic - Indianhead Center Rice Lake Wisconsin
United States Kaiser Permanente Medical Center - Richmond Richmond California
United States Reid Hospital & Health Care Services Richmond Indiana
United States Kaiser Permanente Medical Center - Riverside Riverside California
United States Humphrey Cancer Center at North Memorial Outpatient Center Robbinsdale Minnesota
United States James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester New York
United States Highlands Oncology Group - Springdale Rogers Arkansas
United States Kaiser Permanente Medical Center - Roseville Roseville California
United States Rutherford Hospital Rutherfordton North Carolina
United States Kaiser Permanente Medical Center - Sacramento Sacramento California
United States South Sacramento Kaiser-Permanente Medical Center Sacramento California
United States University of California Davis Cancer Center Sacramento California
United States Seton Cancer Institute at Saint Mary's - Saginaw Saginaw Michigan
United States Heartland Regional Medical Center Saint Joseph Missouri
United States Saint Joseph Oncology, Incorporated Saint Joseph Missouri
United States Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis Saint Louis Missouri
United States CCOP - Metro-Minnesota Saint Louis Park Minnesota
United States Park Nicollet Cancer Center Saint Louis Park Minnesota
United States Regions Hospital Cancer Care Center Saint Paul Minnesota
United States United Hospital Saint Paul Minnesota
United States Cancer Center of Kansas, PA - Salina Salina Kansas
United States Tammy Walker Cancer Center at Salina Regional Health Center Salina Kansas
United States Kaiser Permanente Medical Center - Kaiser Foundation Hospital - San Diego San Diego California
United States Kaiser Permanente Medical Center - San Francisco Geary Campus San Francisco California
United States UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California
United States Kaiser Permanente Medical Center - Santa Teresa San Jose California
United States Kaiser Permanente Health Care San Marcos California
United States Kaiser Foundation Hospital - San Rafael San Rafael California
United States Kaiser Permanente Medical Center - Santa Clara Kiely Campus Santa Clara California
United States Kaiser Permanente Medical Center - Santa Rosa Santa Rosa California
United States Fred Hutchinson Cancer Research Center Seattle Washington
United States Group Health Central Hospital Seattle Washington
United States Harborview Medical Center Seattle Washington
United States Minor and James Medical, PLLC Seattle Washington
United States Polyclinic First Hill Seattle Washington
United States Swedish Cancer Institute at Swedish Medical Center - First Hill Campus Seattle Washington
United States University Cancer Center at University of Washington Medical Center Seattle Washington
United States North Puget Oncology at United General Hospital Sedro-Woolley Washington
United States St. Francis Cancer Center at St. Francis Medical Center Shakopee Minnesota
United States St. Nicholas Hospital Sheboygan Wisconsin
United States Feist-Weiller Cancer Center at Louisiana State University Health Sciences Shreveport Louisiana
United States Mercy Medical Center - Sioux City Sioux City Iowa
United States Siouxland Hematology-Oncology Associates, LLP Sioux City Iowa
United States St. Luke's Regional Medical Center Sioux City Iowa
United States Sanford Cancer Center at Sanford USD Medical Center Sioux Falls South Dakota
United States Kaiser Permanente Medical Center - South San Francisco South San Francisco California
United States CCOP - Upstate Carolina Spartanburg South Carolina
United States Gibbs Regional Cancer Center at Spartanburg Regional Medical Center Spartanburg South Carolina
United States Cancer Care Northwest - Spokane South Spokane Washington
United States Evergreen Hematology and Oncology, PS Spokane Washington
United States Illinois CancerCare - Spring Valley Spring Valley Illinois
United States CCOP - Cancer Research for the Ozarks Springfield Missouri
United States Hulston Cancer Center at Cox Medical Center South Springfield Missouri
United States Regional Cancer Center at Memorial Medical Center Springfield Illinois
United States St. John's Regional Health Center Springfield Missouri
United States Stanford Cancer Center Stanford California
United States Geisinger Medical Group - Scenery Park State College Pennsylvania
United States Mount Nittany Medical Center State College Pennsylvania
United States Iredell Memorial Hospital Statesville North Carolina
United States Marshfield Clinic at Saint Michael's Hospital Stevens Point Wisconsin
United States Saint Michael's Hospital Cancer Center Stevens Point Wisconsin
United States Lakeview Hospital Stillwater Minnesota
United States Kaiser Permanente Medical Facility - Stockton Stockton California
United States Green Bay Oncology, Limited - Sturgeon Bay Sturgeon Bay Wisconsin
United States Flower Hospital Cancer Center Sylvania Ohio
United States SUNY Upstate Medical University Hospital Syracuse New York
United States Allenmore Hospital Tacoma Washington
United States CCOP - Northwest Tacoma Washington
United States Franciscan Cancer Center at St. Joseph Medical Center Tacoma Washington
United States Madigan Army Medical Center - Tacoma Tacoma Washington
United States MultiCare Regional Cancer Center at Tacoma General Hospital Tacoma Washington
United States St. Clare Hospital Tacoma Washington
United States North Suburban Medical Center Thornton Colorado
United States Mercy Hospital of Tiffin Tiffin Ohio
United States CCOP - Toledo Community Hospital Toledo Ohio
United States Medical University of Ohio Cancer Center Toledo Ohio
United States St. Anne Mercy Hospital Toledo Ohio
United States St. Vincent Mercy Medical Center Toledo Ohio
United States Toledo Clinic, Incorporated - Main Clinic Toledo Ohio
United States Toledo Hospital Toledo Ohio
United States Cotton-O'Neil Cancer Center Topeka Kansas
United States Munson Medical Center Traverse City Michigan
United States UVMC Cancer Care Center at Upper Valley Medical Center Troy Ohio
United States Legacy Meridian Park Hospital Tualatin Oregon
United States Arizona Cancer Center at University Medical Center North Tucson Arizona
United States Arizona Cancer Center at University of Arizona Health Sciences Center Tucson Arizona
United States Kaiser Permanente Medical Center - Vacaville Vacaville California
United States Kaiser Permanente Medical Center - Vallejo Vallejo California
United States Legacy Salmon Creek Medical Center Vancouver Washington
United States Northwest Cancer Specialists at Vancouver Cancer Center Vancouver Washington
United States Southwest Washington Medical Center Cancer Center Vancouver Washington
United States Cancer Institute of New Jersey at Cooper - Voorhees Voorhees New Jersey
United States Ridgeview Medical Center Waconia Minnesota
United States Maui Memorial Medical Center Wailuku Hawaii
United States Pacific Cancer Institute - Maui Wailuku Hawaii
United States Kaiser Permanente Medical Center - Walnut Creek Walnut Creek California
United States St. John Macomb Hospital Warren Michigan
United States Central Dupage Cancer Center Warrenville Illinois
United States Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington District of Columbia
United States Waukesha Memorial Hospital Regional Cancer Center Waukesha Wisconsin
United States Fulton County Health Center Wauseon Ohio
United States Cancer Center of Kansas, PA - Wellington Wellington Kansas
United States Wenatchee Valley Medical Center Wenatchee Washington
United States Diagnostic and Treatment Center Weston Wisconsin
United States Marshfield Clinic - Weston Center Weston Wisconsin
United States Ministry Saint Clare's Hospital Weston Wisconsin
United States Exempla Lutheran Medical Center Wheat Ridge Colorado
United States Associates in Womens Health, PA - North Review Wichita Kansas
United States Cancer Center of Kansas, PA - Medical Arts Tower Wichita Kansas
United States Cancer Center of Kansas, PA - Wichita Wichita Kansas
United States CCOP - Wichita Wichita Kansas
United States Via Christi Cancer Center at Via Christi Regional Medical Center Wichita Kansas
United States Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center Wilkes-Barre Pennsylvania
United States Willmar Cancer Center at Rice Memorial Hospital Willmar Minnesota
United States Cancer Center of Kansas, PA - Winfield Winfield Kansas
United States Wake Forest University Comprehensive Cancer Center Winston-Salem North Carolina
United States Marshfield Clinic - Wisconsin Rapids Center Wisconsin Rapids Wisconsin
United States Minnesota Oncology - Woodbury Woodbury Minnesota
United States Kaiser Permanente Medical Cener - Woodland Hills Woodland Hills California
United States UMASS Memorial Cancer Center - University Campus Worcester Massachusetts
United States Ruth G. McMillan Cancer Center at Greene Memorial Hospital Xenia Ohio

Sponsors (2)

Lead Sponsor Collaborator
Southwest Oncology Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of HIV-negative Patients With 2-year Progression-free Survival (PFS) Treated With 2 Initial Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging. Disease progression is defined using the 2007 revised Cheson et al. criteria that is at least 50% increase in sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed, or >= 50% increase in greatest transverse diameter (GTD) of any nodal > 1 cm in shortest axis, or >= 50% increase in the SPD of other target measurable lesions over the smallest sum observed, any new bone marrow involvement, any new lesion, lymph node with long axis is > 1.5 cm or if both long and short axes are > 1 cm, PET positive if patients with no pretreatment PET scan or when PET scan was positive before therapy. Progression-free survival is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact. 2 years
Primary Percentage of HIV-negative Patients Who Are PET-positive After 2 Cycles of ABVD With 2-year PFS Disease progression is defined using the 2007 revised Cheson et al. criteria that is at least 50% increase in sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed, or >= 50% increase in greatest transverse diameter (GTD) of any nodal > 1 cm in shortest axis, or >= 50% increase in the SPD of other target measurable lesions over the smallest sum observed, any new bone marrow involvement, any new lesion, lymph node with long axis is > 1.5 cm or if both long and short axes are > 1 cm, PET positive if patients with no pretreatment PET scan or when PET scan was positive before therapy. Progression-free survival is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact. 2 years
Secondary Percentage of HIV-negative Patients With 2-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging Measured from date of registration to date of death due to any cause. Patients last known to be alive and are censored at date of last contact. 2 years
Secondary Complete and Partial Response Rates for HIV-negative Patients Treated With Response- Adapted Therapy Based on FDG-PET Imaging After 2 Cycles of ABVD Complete Response (CR) is a complete disappearance of all disease with the exception of the following. If no PET scan or when the PET scan was positive before therapy, a post-treatment residual mass of any size is permitted if it is PET negative. If the PET scan was negative before therapy, all nodal masses at baseline must have regressed. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow (BM) must be negative if positive at baseline. Normalization of markers. Partial Response (PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. If PET scan or when the PET scan was positive before therapy, PET should be positive in at least one previously involved site. 7 months after registration
Secondary Number of HIV-negative Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal. Up to 1 year
Secondary Percentage of HIV-positive Patients With 2-year Progression-free Survival (PFS) Treated With Initial 2 Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging. Disease progression is defined using the 2007 revised Cheson et al. criteria that is at least 50% increase in sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed, or >= 50% increase in greatest transverse diameter (GTD) of any nodal > 1 cm in shortest axis, or >= 50% increase in the SPD of other target measurable lesions over the smallest sum observed, any new bone marrow involvement, any new lesion, lymph node with long axis is >1.5 cm or if both long and short axes are > 1 cm, PET positive if patients with no pretreatment PET scan or when PET scan was positive before therapy. progression-free survival is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact. 2 years
Secondary Percentage of HIV-positive Patients With 5-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging. Measured from date of registration to date of death due to any cause. Patients last known to be alive and are censored at date of last contact. 5 years
Secondary Complete and Partial Response Rates for HIV-positive Patients Treated With Response-Adapted Therapy Based on FDG-PET Imaging After 2 Cycles of ABVD Complete Response (CR) is a complete disappearance of all disease with the exception of the following. If no PET scan or when the PET scan was positive before therapy, a post-treatment residual mass of any size is permitted if it is PET negative. If the PET scan was negative before therapy, all nodal masses at baseline must have regressed. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow (BM) must be negative if positive at baseline. Normalization of markers. Partial Response (PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. If PET scan or when the PET scan was positive before therapy, PET should be positive in at least one previously involved site. 7 months after registration
Secondary Number of HIV-positive Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal. Up to 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1